Who are NiCord® (omidubicel)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Allogenix Plus, Deramiocel (CAP-1002), JTA-004.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nicord-omidubicel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

NiCord® (omidubicel) — Competitive Intelligence Brief

NiCord® (omidubicel) (NiCord® (omidubicel)) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Allogeneic cell therapy. Area: Hematology/Oncology.

phase 3 Allogeneic cell therapy Hematology/Oncology Small molecule Live · refreshed every 30 min

Target snapshot

NiCord® (omidubicel) (NiCord® (omidubicel)) — Gamida Cell ltd. Omidubicel is an ex vivo expanded allogeneic umbilical cord blood-derived hematopoietic progenitor cell product that enhances hematopoietic recovery after transplantation.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
NiCord® (omidubicel) TARGET	NiCord® (omidubicel)	Gamida Cell ltd	phase 3	Allogeneic cell therapy
Allogenix Plus	Allogenix Plus	University of Missouri-Columbia	marketed	Allogeneic cell therapy
Deramiocel (CAP-1002)	Deramiocel (CAP-1002)	Capricor Inc.	phase 3	Allogeneic cell therapy
JTA-004	JTA-004	Bone Therapeutics S.A	phase 3	Allogeneic cell therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Allogeneic cell therapy class)

Capricor Inc. · 2 drugs in this class
Aivita Biomedical, Inc. · 1 drug in this class
Bone Therapeutics S.A · 1 drug in this class
Gamida Cell ltd · 1 drug in this class
University of Missouri-Columbia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NiCord® (omidubicel) — Competitive Intelligence Brief. https://druglandscape.com/ci/nicord-omidubicel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab